ESI-GROUP
29.11.2021 17:02:13 CET | Business Wire | Press release
Regulatory News:
ESI Group (ISIN Code: FR0004110310, Symbol: ESI) (Paris:ESI) announces today the completion of its new leadership team from seasoned professionals from the current organization and the appointment of Ajit Gokhale as Executive Vice-president Engineering.
Cristel de Rouvray, Chief Executive Officer of ESI Group says : "With the release of our “OneESI 2024 – Focus to Grow” plan two months ago, we are engaged in a profound transformation. To lead our Group and this transformational effort, I can count on the full support of my new Leadership Team which is composed of nine impressive, complementary and highly experienced individuals. I’m also proud to welcome in our team Ajit Gokhale who will play a key role in our organization and more specifically in our software engineering strategy and execution. Together, we are entirely committed to bring our company to the next level and to transform it as one of the key leading software partners for industry.”
Creation of a new leadership team
The Group unveils a new Leadership Team, now composed of:
- Cristel de Rouvray : Chief Executing Officer
and, in alphabetical order:
- Yannick Charron : Vice-president Human Resources
- Ajit Gokhale : Executive Vice-president Engineering
- Francis Griffiths : Executive Vice-president Sales
- Dominique Lefebvre : Senior Vice-president Product Development Planning
- Emmanuel Leroy : Executive Vice-president Product, Innovation & Industry Solutions
- Corinne Romefort-Régnier : Senior Vice-president General Secretary & Governance
- Mike Salari : Corporate Chief Operating Officer Revenue Generation
- Olfa Zorgati : Executive Vice-president, CFO & Operations
Nomination of Ajit Gokhale as EVP Engineering
Ajit Gokhale, 54 years old, brings over 30 years of high-tech Research & Development and business experience to ESI. He has extensive knowledge with customers in automotive, consumer electronics, semiconductor, and energy industries as well as the academic segment, that use technical and scientific software. Ajit Gokhale will lead the Software Engineering organization at ESI to transform its software into complete chained solutions, as defined and prioritized by the Industry Solutions team, to serve key industry and customer segments. Ajit reports to Cristel de Rouvray, Chief Executive Officer of ESI Group.
Ajit Gokhale has spent a significant amount of his career within NI (NATI: NASDAQ) in the US, Europe and Asia. He has held leadership roles such as vice president of data acquisition, vice president of sales and marketing of Asia-Pacific, managing director of the United Kingdom, France, and China, and section manager for data acquisition research and development. For the past two years, Ajit held a senior role at Bloomy.
Ajit Gokhale holds a bachelor’s degree in electrical engineering and computer science from the Massachusetts Institute of Technology.
Upcoming events
- FY21 sales and results - February 28th , 2022
About ESI Group
Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time, while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval, energy and heavy industry, ESI is present in more than 20 countries, employs 1200 people around the world and reported 2020 sales of €132.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211129005541/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom